Research programme: immune checkpoint anticancer therapies - Shire/Symphogen

Drug Profile

Research programme: immune checkpoint anticancer therapies - Shire/Symphogen

Alternative Names: Immune checkpoint therapies - Shire/Symphogen

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxalta; Symphogen
  • Developer Shire; Symphogen
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Checkpoint kinase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 04 Jan 2016 Baxalta and Symphogen agree to co-develop Immune checkpoint therapies for Cancer
  • 04 Jan 2016 Early research in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top